<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Choroid Plexus Epithelial Cells</th>
</tr>
<tr>
<td class="label">Location</td>
<td>Choroid plexus (lateral, third, fourth ventricles)</td>
</tr>
<tr>
<td class="label">Marker Genes</td>
<td>TTR (transthyretin), AQP1 (aquaporin 1), KCNQ1, SLC12A2 (NKCC1)</td>
</tr>
<tr>
<td class="label">Developmental Origin</td>
<td>Neuroectoderm, roof plate</td>
</tr>
<tr>
<td class="label">Key Functions</td>
<td>CSF production, BCSFB, molecular filtration</td>
</tr>
<tr>
<td class="label">Taxonomy</td>
<td>ID</td>
</tr>
<tr>
<td class="label">Cell Ontology (CL)</td>
<td>[CL:0000706](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000706)</td>
</tr>
<tr>
<td class="label">Database</td>
<td>ID</td>
</tr>
<tr>
<td class="label">Cell Ontology</td>
<td>[CL:0000706](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000706)</td>
</tr>
<tr>
<td class="label">Cell Ontology</td>
<td>[CL:4301608](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_4301608)</td>
</tr>
</table>
<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Choroid Plexus Epithelial Cells</th>
</tr>
<tr>
<td class="label">Location</td>
<td>Choroid plexus (lateral, third, fourth ventricles)</td>
</tr>
<tr>
<td class="label">Marker Genes</td>
<td>TTR (transthyretin), AQP1 (aquaporin 1), KCNQ1, SLC12A2 (NKCC1)</td>
</tr>
<tr>
<td class="label">Developmental Origin</td>
<td>Neuroectoderm, roof plate</td>
</tr>
<tr>
<td class="label">Key Functions</td>
<td>CSF production, BCSFB, molecular filtration</td>
</tr>
<tr>
<td class="label">Taxonomy</td>
<td>ID</td>
</tr>
<tr>
<td class="label">Cell Ontology (CL)</td>
<td>[CL:0000706](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000706)</td>
</tr>
<tr>
<td class="label">Database</td>
<td>ID</td>
</tr>
<tr>
<td class="label">Cell Ontology</td>
<td>[CL:0000706](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000706)</td>
</tr>
<tr>
<td class="label">Cell Ontology</td>
<td>[CL:4301608](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_4301608)</td>
</tr>
</table>
Choroid plexus epithelial cells (CPECs) are specialized ependymal cells that form the blood-cerebrospinal fluid barrier (BCSFB) and produce cerebrospinal fluid. They represent a critical interface between the peripheral circulation and the central nervous system, playing increasingly recognized roles in neurodegenerative disease pathogenesis. [@schwarzman2004]
The choroid plexus consists of:
Unlike the BBB, the BCSFB has:
CPECs produce CSF via:
CPECs express:
The choroid plexus undergoes significant alterations in AD:
TTR Dysregulation: Transthyretin, normally produced by CPECs, has been shown to have protective effects against amyloid-beta aggregation. In AD, TTR expression is reduced, diminishing this neuroprotective function [1](https://pubmed.ncbi.nlm.nih.gov/12676788/).
CSF Production Decline: Age-related and AD-associated reductions in CSF production correlate with impaired clearance of metabolic waste products, including amyloid-beta and tau. Studies show CSF production decreases approximately 0.3% per year after age 50, with accelerated decline in AD patients [2](https://doi.org/10.1212/WNL.0000000000002495).
Barrier Breakdown: The BCSFB becomes "leakier" in AD, with disrupted tight junctions allowing peripheral proteins and potential neurotoxins into the CSF compartment. This compromise is associated with increased neuroinflammation [3](https://pubmed.ncbi.nlm.nih.gov/25672610/).
Iron Dyshomeostasis: CPEC iron transport dysfunction contributes to brain iron accumulation observed in AD. The transferrin receptor-mediated iron import becomes dysregulated, leading to oxidative stress [4](https://doi.org/10.1007/s12017-019-08569-z).
CPEC involvement in PD includes:
α-Synuclein Clearance: The choroid plexus can export α-synuclein through organic anion transporters. Impaired CPEC function may reduce clearance of toxic α-synuclein species from the CSF [5](https://pubmed.ncbi.nlm.nih.gov/28750445/).
Neuroinflammation: CPECs respond to systemic inflammation by producing cytokines that can propagate neuroinflammatory processes relevant to PD pathogenesis. The BCSFB serves as a conduit for peripheral immune signals [6](https://doi.org/10.1016/j.jneuroim.2019.02.016).
Drug Delivery: Reduced CPEC transporter function may limit delivery of therapeutic agents to the CNS in PD patients, contributing to treatment challenges [7](https://pubmed.ncbi.nlm.nih.gov/23528656/).
CSF Secretion Abnormalities: CPEC dysfunction may contribute to altered CSF composition in ALS, affecting motor neuron microenvironment. Studies show changes in CSF protein profiles correlate with disease progression [8](https://doi.org/10.1016/j.neurobiolaging.2018.02.025).
Barrier Permeability: Increased BCSFB permeability has been documented in ALS, potentially allowing toxic substances access to the CNS [9](https://pubmed.ncbi.nlm.nih.gov/26640156/).
CPECs show:
CPEC transporters can be leveraged for CNS drug delivery:
CPEC-derived markers may serve as disease biomarkers:
The study of Choroid Plexus Epithelial Cells has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.